Ticker Hub
BYSI — AI Analysis & Sentiment
3 recent AI-generated analyses for BYSI. Sentiment and confidence insights updated continuously.
BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026
BeyondSpring presented strong Phase 2 data for Plinabulin in NSCLC, showing durable clinical benefits and improved survival rates compared to histo...
Jun 2, 2026BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
BeyondSpring's Q1 2026 results show a concerning increase in net loss and a high cash burn rate for a clinical-stage company. This deteriorating fi...
May 13, 2026BeyondSpring Reports 2025 Year-End Financial Results
BeyondSpring made significant advancements in its clinical pipeline, with positive Plinabulin Phase 3 data and a planned confirmatory trial, alongs...
Mar 25, 2026